Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution.
Acute Disease
Allografts
/ immunology
B-Lymphocytes, Regulatory
/ immunology
Biomarkers
/ metabolism
Bronchoalveolar Lavage
Chronic Disease
Female
Graft Rejection
/ blood
Humans
Leukocytes, Mononuclear
/ metabolism
Lung Transplantation
/ adverse effects
Lymphocyte Subsets
/ immunology
Male
Middle Aged
Multivariate Analysis
Principal Component Analysis
Pulmonary Alveoli
/ immunology
T-Lymphocytes, Regulatory
/ immunology
acute rejection
bronchiolitis obliterans syndrome
chronic lung allograft dysfunction
effector T cells
flow cytometry
lung transplantation
regulatory cells
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
16
02
2021
revised:
28
03
2021
accepted:
29
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
25
2
2023
Statut:
epublish
Résumé
The immune mechanisms occurring during acute rejection (AR) and chronic lung allograft dysfunction are a challenge for research and the balance between effector and regulatory cells has not been defined completely. In this study, we aimed to elucidate the interaction of effector cells, mainly Th17, Th1 and Th2, and regulatory cells including (CD4 Bronchoalveolar lavage cells (BAL) and peripheral blood mononuclear cells (PBMCs) from stable lung transplanted (LTx )subjects ( A predominance of Th17 cells subtypes in the PBMCs and BAL and a depletion of Tregs, that resulted in decrease Treg/Th17 ratio, was observed in the AR group. CD19 In AR, BOS and stable lung transplant, regulatory and effector cells clearly demonstrated different pathways of activation. Understanding of the balance of T cells and T and B regulatory cells can offers insights into rejection.
Sections du résumé
BACKGROUND
The immune mechanisms occurring during acute rejection (AR) and chronic lung allograft dysfunction are a challenge for research and the balance between effector and regulatory cells has not been defined completely. In this study, we aimed to elucidate the interaction of effector cells, mainly Th17, Th1 and Th2, and regulatory cells including (CD4
METHODS
Bronchoalveolar lavage cells (BAL) and peripheral blood mononuclear cells (PBMCs) from stable lung transplanted (LTx )subjects (
RESULTS
A predominance of Th17 cells subtypes in the PBMCs and BAL and a depletion of Tregs, that resulted in decrease Treg/Th17 ratio, was observed in the AR group. CD19
CONCLUSIONS
In AR, BOS and stable lung transplant, regulatory and effector cells clearly demonstrated different pathways of activation. Understanding of the balance of T cells and T and B regulatory cells can offers insights into rejection.
Identifiants
pubmed: 33916034
pii: cells10040780
doi: 10.3390/cells10040780
pmc: PMC8065700
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : OTT organizzazione toscana trapianto
ID : Respir1, Prot n 15732, 16 September 2019
Références
Cell Death Dis. 2018 Jan 25;9(2):109
pubmed: 29371592
Semin Immunopathol. 2011 Mar;33(2):117-27
pubmed: 21424593
Transpl Int. 2020 May;33(5):503-516
pubmed: 31903646
Nat Commun. 2017 Mar 14;8:14649
pubmed: 28290453
Oncotarget. 2015 Oct 20;6(32):33486-99
pubmed: 26378021
Sci Rep. 2018 Jan 15;8(1):703
pubmed: 29335495
Clin Exp Med. 2019 Nov;19(4):487-494
pubmed: 31485847
Mediators Inflamm. 2016;2016:6309219
pubmed: 27413254
Scand J Immunol. 2021 Feb 19;:e13031
pubmed: 33606277
Transplantation. 2008 Apr 15;85(7):1056-9
pubmed: 18408589
Arch Pathol Lab Med. 2017 Mar;141(3):437-444
pubmed: 27819763
Eur Respir J. 2018 Mar 1;51(3):
pubmed: 29449421
Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(1):2-7
pubmed: 33093763
Eur Respir J. 2014 Dec;44(6):1479-503
pubmed: 25359357
Int J Mol Sci. 2018 Mar 03;19(3):
pubmed: 29510522
BMC Pulm Med. 2017 Jul 18;17(1):102
pubmed: 28720146
Intern Emerg Med. 2020 Oct;15(7):1247-1254
pubmed: 32078140
Inflammation. 2014 Feb;37(1):10-6
pubmed: 23912648
Cell Mol Immunol. 2018 May;15(5):458-469
pubmed: 29563615
J Clin Cell Immunol. 2016 Apr;7(2):
pubmed: 27308096
Nat Rev Rheumatol. 2015 Oct;11(10):562
pubmed: 26369609
Panminerva Med. 2020 Sep;62(3):143-149
pubmed: 32192319
Immunity. 2015 Apr 21;42(4):607-12
pubmed: 25902480
Cell Immunol. 2012;274(1-2):89-97
pubmed: 22361174
Arthritis Rheumatol. 2014 Oct;66(10):2849-61
pubmed: 24942956
Ann Transl Med. 2020 Mar;8(6):418
pubmed: 32355862
Transplant Direct. 2020 Apr 09;6(5):e547
pubmed: 32548241
J Heart Lung Transplant. 2020 Aug;39(8):761-770
pubmed: 32418864
J Immunol. 2019 Oct 15;203(8):2110-2120
pubmed: 31511354
Semin Immunopathol. 2011 Mar;33(2):129-34
pubmed: 21279808
Transplantation. 2009 Aug 27;88(4):521-7
pubmed: 19696635
Lung. 2015 Oct;193(5):677-81
pubmed: 26216722
J Am Geriatr Soc. 1986 Oct;34(10):728-34
pubmed: 2944942
Biomed Res Int. 2017;2017:8431838
pubmed: 29259988
J Pathol. 2008 Jan;214(2):276-82
pubmed: 18161753
Int Immunopharmacol. 2021 Mar 11;95:107525
pubmed: 33714885
Transplant Proc. 2012 May;44(4):1035-40
pubmed: 22564619
Sci Transl Med. 2013 Feb 20;5(173):173ra23
pubmed: 23427243
Arthritis Res Ther. 2015 Nov 30;17:344
pubmed: 26617177
Inflammation. 2020 Apr;43(2):393-400
pubmed: 31853715
Clin Exp Med. 2020 May;20(2):207-216
pubmed: 31970550